

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following Grade 3 adverse events was most commonly reported by patients receiving capivasertib for previously treated HR-positive, HER2-negative advanced breast cancer on the Phase III CAPItello-291 study?
 - a. Infection
 - b. Rash**
 - c. Hyperphosphatemia
 - d. Blurred vision
2. What was the approximate reduction in the risk of disease progression or death with inavolisib for patients with HR-positive, HER2-negative advanced breast cancer with PIK3CA mutation in the Phase III INAVO120 trial?
 - a. 11%
 - b. 22%
 - c. 57%**
 - d. 79%
3. Patritumab deruxtecan targets which of the following proteins?
 - a. HER2
 - b. HER3**
 - c. LIV1A
 - d. TROP2
4. In the POSITIVE trial, approximately what proportion of women with HR-positive breast cancer who paused endocrine treatment for up to 2 years had at least 1 pregnancy?
 - a. 20%
 - b. 40%
 - c. 62%
 - d. 74%**
5. Which of the following patients with HR-positive, HER2-negative localized breast cancer derived an invasive disease-free survival (iDFS) benefit with adjuvant ribociclib in combination with endocrine therapy according to final iDFS analysis of the Phase III NATALEE trial?
 - a. Patients with node-negative disease
 - b. Patients with node-positive disease
 - c. Both a and b**
 - d. Neither a nor b